Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Study of SKB264 in Advanced Solid Tumors
2023-508700-38-00Phase 2Completed
- Sponsor
- Kelun-Biotech
- Start
- Jun 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan in solid tumor and Nonhematologic neoplasms, sponsored by Kelun-Biotech. Started Jun 2024; status: completed.
02
Drugs
sacituzumab tirumotecan
03
Conditions
solid tumorNonhematologic neoplasms
Beyond the preview
Go deeper on 2023-508700-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508700-38-00.